Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q1'25

By Inderes4/24/2025, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:01

Please go ahead.

Christine Lind
00:03 - 13:44

Thank you. Operator. And welcome to the presentation of Bactiguard's Q1 2025 report. Our CFO, Patrick Bach, and I will go through the presentation together. And as usual, we will have a Q&A session towards the end. I will begin by sharing some brief comments on the first quarter results, and Patrick will go through the financials in more detail later in the presentation. Firstly, we are very pleased to again report both continued profitability and revenue growth. We delivered an EBITDA of 9.4 million SEK and revenues of 62.7 million SEK, which is an increase of almost 7% compared to Q1 last year. Increased license revenues stem primarily from our strengthened collaboration with medtech company BD. A prime example of a mutually beneficial relationship that is driving growth for both parties. I will provide a more detailed update regarding the BD partnership shortly. Another highlight for Q1 comes from our wound management portfolio. Revenues increased by more than 50%, driven by sales of our Hydrocyn aqua line of products. We now have four quarters in a row with positive financial development, demonstrating that we are consistently doing what we said we would do and delivering on our promise of profitability. Following the financial turnaround and strategic shift from 2024 as a major event during the quarter, in early March, we announced our updated strategic and financial targets to be achieved by the year-end 2030, and I will take this opportunity to repeat them. First, more than ten application areas in exclusivity or licensed partnerships. Second, revenues of at least 600 million SEK and third, an EBITDA of at least 200 million SEK in connection with the targets. We also revised our focus on therapeutic areas for the licensed business, and I will also come back to this in a couple of slides. As I noted in the CEO statement in the report, we have established a solid foundation to achieve the updated strategic and financial targets, while at the same time maintaining a clear focus on growth and profitability. In short, Bactiguard has had a great start to 2025. Before we go into more detail on the quarter itself, I wanted to reflect on the reason we are here to begin with. Infection prevention continues to be a critical global medical need, and the demand for effective solutions is more pressing than ever due to the challenges faced by healthcare providers. Healthcare-associated infections are very common, with 1 in 10 patients worldwide affected by HAIs. 40 to 60% of all HAIs are caused by medical devices, and the costs associated with HAIs are significant, related to longer hospitalizations and the additional need for treatments. HAIs, however, can be significantly reduced through proactive infection prevention strategies, and it is estimated that up to 50% of all HAIs are preventable. According to the World Health Organization, proactive infection prevention is a core pillar to avoiding AMR while also being cost-effective. Bactiguard's infection prevention technology is a real solution to this challenge with its ultra-thin layer of noble metals: gold, silver, and palladium, which has been demonstrated to work on multiple types of materials and devices and in different clinical settings. Our technology has amassed a wealth of real-world evidence of its safety and efficacy in reducing medical device-related infections. This technology platform endures beyond today's market volatility. Through partnerships with leading medtech companies, we enable differentiated medical devices to reach a broad global market. With infection prevention as our overarching theme. Our focus within the license business is to continue to strengthen existing partnerships, such as our excellent collaboration with BD, while simultaneously seeking new business relationships in additional application areas. Another pillar of our strategy is the continuous enhancement of our knowledge and specialist expertise. To further reinforce collaborations within our current partnerships, we will continue investing in critical competency areas such as research and development, medical, and regulatory. These investments are also essential to drive new business and partnership development. Our ambition is to always be the best partner to our partners by aligning with positive outcomes for them. We similarly achieve positive outcomes for Bactiguard Holding AB within our Wound Management portfolio. The focus is on continuing profitable growth and expansion into new markets. The need for infection prevention that I highlighted earlier spans our strategic therapeutic areas and presents significant opportunities for ZNN Bactiguard. In the left column, we show the prioritized therapeutic areas for the licensed business, which were revised in connection with the 2030 targets. Orthopedics, Cardiology, Neurology. Urology and vascular access. Each of these includes relevant application areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device-related infections, and where there is commercial and realizable potential for Zimmer Biomet and Bactiguard. Orthopedics holds great potential in an addressable market of almost $40 billion, with a wide array of relevant application areas covering implants throughout the body. This area also has a significant number of procedures performed and a correspondingly high number of device-related infections. Rates of infection can also be very significant, especially in fracture and trauma-associated procedures, where these rates can reach up to 40%. In addition to our existing relationship with Zimmer Biomet in trauma, we are actively seeking new licensed partners for other orthopedic categories. Cardiology and neurology are newer therapeutic areas for Bactiguard, but present significant potential both in terms of market sizes of ten billion and nine billion USD, respectively, as well as meaningful infection rates associated with implantable devices across various application areas. These devices include materials that Bactiguard Holding AB coated, and we have expertise in the area, including through our board members, Anna Martling, Professor of Surgery at Karolinska Institutet, and Doctor Rick Kuntz, former Chief Medical and Scientific Officer at Medtronic and an expert in cardiology and clinical research within urology. We have our well-established partnerships for Foley catheters, but we see continued growth potential in this therapeutic area. In other applications. Beyond the Foley's, vascular access is an area where Bactiguard has had its own approved CVC product in the portfolio, demonstrating our ability to coat and to bring to market relevant products in this category. Across the top of the chart are our partnership journey stages, against which we will communicate progress in our business development activities. In the far right column, we have our existing relationships at the license partnership stage with products on the market in the relevant therapeutic area. We will continue to communicate both license and exclusivity partnerships to the market with our partner company and the application area included in the collaboration, along with any other material aspects of the collaboration. Our activities at the two earlier phases of application development and material transfer will be disclosed by therapeutic area, and we will not disclose more details around the companies or indeed the number of active collaborations. The specific timeline from early feasibility under an MTA through to a marketed product can vary based on device class, desired product claims, and the associated time to deliver the data demonstrating efficacy and safety. The partnership journey from early-stage testing to commercialization can take, on average, 5 to 7 years, as we have communicated previously along the journey. Partners can enter exclusivity with Bactiguard for a particular area, and this is the point at which we will announce who the partner is and what we are working on together. By the time of market approval and launch, we will update the status of our specific partnerships on a regular basis, as we do with our existing license partnerships. In addition to these licensed partnerships shown here, Bactiguard is currently working in early feasibility and performance testing under material transfer agreements within the category of vascular access, as well as in categories that are outside of the highlighted strategic therapeutic areas. While these named therapeutic areas remain the focus of our proactive efforts, we will work on selected opportunities outside of these therapeutic areas where we and our potential partners believe there is a clear need for infection prevention and see potential in our technology. This snapshot will be presented in connection with our quarterly reports or when we announce new exclusivity or license partnerships. Now let's take a closer look at our partnership, starting with the global medtech company BD. During the first quarter, we continued our active collaboration spanning the entire value chain, from technology licensing to go-to-market strategies. This is really a model partnership built on newly fully aligned incentives, coupled with mutual trust and respect, thus enabling win-win outcomes for both collaboration partners. One example from this past March is when Bactiguard Holding AB and BD attended an important healthcare conference in India. CRITICARE 2025 brings together intensivists, anesthesiologists, emergency physicians, and other healthcare professionals dedicated to critical care in India. Addressing such a broad audience together marked an important step in informing local stakeholders and key opinion leaders that BD is taking over the sales and distribution of Bactiguard-coated Foley catheters in India. Following BD's successful market registration late last year, BD is also relaunching the Bactiguard Covid Foley catheters Bardex IC in the US, and a new product website is already available for viewing. In addition, we continue our joint work on the market registrations required to enable BD launches in new markets, like the one achieved in India. There is clear demand across markets, and we receive many inquiries from both healthcare professionals and patients about when the Catheter products will be transferred and available in their respective markets. That level of engagement from the healthcare community is the strongest endorsement our technology can receive. Within the Trauma Partnership collaboration. Zimmer Biomet has focused on the commercialization of the ZNN Bactiguard-coated orthopedic trauma implant. Now, in existing markets during the first quarter, we also continued to work actively on the processes to retain regulatory approval under MDR in Europe and thus required to enable continued commercialization. The post-market clinical trials in Europe on Bactiguard Holding AB continue and will gather data on infection rates, safety, and clinical outcomes. Both the MDR registration and clinical trial work are expected to continue for the next couple of years. Our wound management portfolio had a really strong first quarter with a revenue increase of more than 50%. The increase was fueled by a significant rise in sales of the Hydrocyn aqua branded range of products. In April, we hosted a panel with international wound care experts and specialists to discuss Clean to Heal, a thought leadership concept emphasizing the importance of effective debridement and cleansing to promote healing. The conversation resulted in a consensus report published in Wounds International, a peer-reviewed journal with a long-standing reputation for advancing global wound care through evidence-based insights and expert-led clinical guidance. During the quarter, our Malaysian production site was also formally certified ISO 14001 from the British Standards Institution. Manifesting our commitment to high-quality and responsible manufacturing and production processes. Reiterating the strategy for Wound Management, we remain focused on stable profitability and expansion into new markets, primarily in Asia. And now I will hand over to Patrick to review our Q1 financial outcomes in more detail.

Patrick Bach
13:46 - 19:17

By the time of market approval and launch, we will update on the status of our specific partnerships on a regular basis, as we do with our existing license partnerships. Christine. I am pleased to present the financial results for our first quarter of what is indeed a new year. In short, we deliver continued profitability and growth. Positive EBITDA now for the fourth quarter in a row and good growth across our core business, driven by both our licensed business as well as our wound management portfolio. Total revenue grew by approximately 7% to 663 million in Q1, driven by license and wound management. Net sales increased to about 59 million, or 6%, adjusted for currency. In particular, we saw a high double-digit growth of 51% from the wound management portfolio to a total of 19 million for the quarter, again driven by Hydrocyn aqua growing in both existing and new markets. With the positive quarter, we grew our rolling 12 months, or RTM, to 266 million in total revenue, again driven by growth from both our license and wound management portfolio. The portfolio is, as planned and announced, phased out and will not contribute any significant revenue in 2025. Now, turning to our core license business. We saw first-quarter revenue growth of 12% to a total of 39 million, as detailed in our report. This was driven by revenue growth of 15% from existing license partners, i.e. with products in the market. Notably, revenues from BD were at 32 million, up about 4 million, or 8.5%, adjusting for positive currency effects. Revenue from Zimmer Biomet for Q1 2025 came in just under a million at 0.9 million, and pertains mainly to royalties from in-market trauma products. This Q1 2025 came in just under a million at 0.9 million, and pertains mainly to royalties from in-market trauma products. We report no significant exclusivity revenues nor application development revenues in Q1. Now, with the Q1 growth, our license revenue on a TTM basis grew to almost 169 million, again driven by revenue from our in-market license partners, growing to 162 million in RTM. On OpEx. We continue to operate diligently and with cost control in Q1. Our total operating costs decreased by 13% to 42 million for the quarter. Approximately 7 million in total net savings. And these savings were driven by both personnel costs and operating expenses. Now, on a rolling 12-month basis, we see our OpEx coming down close to the 200 level, with 201 million. In Q1, we continued to improve our profitability, with EBITDA coming in at 9.4 million, an increase of almost 11 million compared to the negative result of Q1 last year. The improved Q1 result was mainly driven by the increase in total license revenues, as well as the high wound management growth, while continuing to keep our costs under control. Now, on a rolling 12-month basis, we are reporting an EBITDA of 28.9 million. Finally, Q1 operating loss amounted to 2.6 million, yet an improvement of about 10 million versus the first quarter last year. Our net result for the period amounted to a loss of 4.7 million, versus a 9.9 million loss last year. On cash flow, notably, our cash position decreased in Q1 with the planned and announced repayment of 51 million on loans. As we have completed a refinancing with ACP until 2028. For the first quarter period, we report cash flow from operating activities at -12 million and cash flow from financing activities at -55 million, including the repayments, while negative at 12 million. The cash flow from operating activities improved by 7 million compared to last year and was driven mainly by a change in net working capital, primarily accounts receivables of -10 million. All in all, our cash position decreased to 46.8 million at the end of Q1, again mainly driven by the voluntary repayment on loans of 51 million SEK. With that, back to you, Christine.

Christine Lind
19:19 - 22:23

Thank you, Patrick. Time to sum up today's call with some key takeaways. We have had a great start to 2025 and delivered both continued EBITDA profitability and revenue growth, marking the fourth consecutive quarter of this achievement. Our BD collaboration is the solid backbone driving license revenue growth this quarter, as well as the greatest example of a mutually beneficial partnership to continue to build on going forward. Wound management also contributed meaningfully in Q1, where our main brand, Hydrocyn aqua, was the shining star of the quarter with a strong uptick in sales. We are excited about the opportunity represented by our five refined strategic therapeutic areas for the licensed business, concentrating on where Bactiguard technology offers the greatest and most realizable potential. In essence, areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device-related infections. This was also reflected in our updated targets, delivering at least 600 million SEK in revenue and at least 200 million SEK in EBITDA by year-end 2030, supported by a goal of securing at least ten application areas in exclusivity or licensed partnerships. Our scalable business model, combined with strong operational leverage, is expected to deliver significant value even beyond 2030. Through partnerships established in the years ahead. While we have delivered a solid first quarter, I want to acknowledge that global market conditions are more volatile and unpredictable than ever. Although ZNN Bactiguard is not immune, we believe that companies with a clear long-term strategy and strong fundamentals are better positioned to navigate turbulent times. Our current assessment of the US tariff situation is that Bactiguard is not directly impacted. However, we do have substantial US dollar exposure in our licensed business, and a weaker US dollar will negatively affect our results. We will continue to monitor developments closely in this evolving landscape. Amid this uncertainty, the relevance of our technology remains crystal clear. It offers a real solution to a challenge that extends far beyond short-term market volatility. The issue of healthcare associated infections. The interest in our unique infection prevention technology continues to grow, both among existing partners and potential new collaborators. We have now established a solid foundation to achieve the updated strategic and financial targets, while at the same time maintaining a clear focus on growth and profitability. Most importantly, we are doing what we set out to do. We're delivering on our promise following the financial turnaround and strategic shift in 2024. And with Q1, we continue to deliver consistent results. And with that, I would like to hand over to the operator to open up for questions.

Operator
22:25 - 22:47

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.

Unknown 1
22:50 - 23:27

Two questions. First one, on the partner revenues, it seems that, although you don't report that separately. But if you do, the backward calculation suggests that sales from China have increased quite significantly. Is this only related to China? And could you describe how volatile that revenue line is? And then a question on the raw material cost. That is up significantly here as a percentage of sales compared to what we saw in the third and fourth quarter. If you could explain the reason for that. Thank you.

Patrick Bach
23:29 - 24:30

Yes. Hi, Christopher Patrick here. Thank you for your question. Uh, in brief, yes, you are correct. Uh, we do have sales to our license partner in China. Well, Valide is part of our, uh, existing license partner revenues. However, we don't spell that out directly. Um, we do see growth quarter over quarter. Yes. Um, however, it's also important to note that historically, our sales, uh, our revenues coming from valid in China tend to be a bit lumpy. Uh, we do not expect significant, uh, revenue growth from China this year compared to last year. And to your question regarding the raw materials. Um, it depends on the different partners we sell to. So, yes, we did have a slightly higher cost of goods in Q1 versus last year.

Unknown 1
24:36 - 24:45

Is it? But is it an effect of, um, Zimmer Biomet, uh, sales becoming smaller?

Patrick Bach
24:46 - 25:09

And not directly, but the change in COGS in this case is mainly related to sales to China. Um, but obviously if we do not report any, for example, exclusivity revenues, uh, which are milestone fees, then that also changes the margins clearly.

Unknown 1
25:09 - 25:12

Yeah. Makes sense. Okay, good. Thank you.

Patrick Bach
25:12 - 25:13

Thank you.

Operator
25:16 - 25:20

The next question comes from Mathias, from SEB. Please go ahead.

Unknown 2
25:24 - 25:47

Hello. Thanks for taking my questions today. I have three questions. So starting off, could you elaborate a little bit more on the high wound management sales? Um, I guess, should we view this as a new sort of level, or were there any favorable large orders for Hydrocyn aqua in this quarter that we should consider when trying to model it going forward?

Patrick Bach
25:49 - 26:38

Thanks, Mathias. I'll answer your first question quickly. Um, as stated, we did see higher than expected growth in the quarter on Wound Management coming from both existing and some selected new markets, where we have not seen growth before. U.S. We see overall strong, continued double-digit profitability from the Wound Management portfolio. Uh, I would say when we see double-digit growth, we certainly don't mean that we will deliver over 50% every single quarter. And you will find that the comparable period in Q1 2024, as it was in 2023, is also typically a low quarter for our wound management sales.

Unknown 2
26:42 - 27:08

Okay. Thank you. And then on OpEx, I think there was good cost control in this quarter. Disregarding the cost of raw materials already discussed. So would you say this level is reflective of what can be anticipated this year? Or are you expecting a certain volatility in, let's say, personnel expenses and other external costs? That's the second one.

Patrick Bach
27:10 - 28:13

Yep. Good. Good question. Um, we do report low OpEx this quarter versus last year, but also versus our run rate. Uh, the last 12 months, I would say our rolling 12 months is now at a 200 million level. Uh, we do see some intra-quarter changes that relate to the changes coming out of the transformation we did last year. But of course, we will also continue to invest in strengthening the organization where we see the need. Uh, but overall, we feel that we have taken out a significant part of our operating expenses in the business. We will continue to have cost control. Um, but obviously, we will not continue to reduce costs at the same level as we have done in the last 12 months. We will continue to invest in our organization. Um, but we will continue our focus on growing profitability as well.

Unknown 2
28:15 - 28:46

Thank you very much. And then the last one. Um, so how should we look upon the work to find new partners in related therapeutic areas? I think you said interest is increasing, which is good to hear, but do you have any insights on how you are working with it? How many ongoing dialogues are there, and if that has changed anything in the recent 12 or 24 months? So answers to all of those questions and insights would be helpful. That's my last one. Thank you very much.

Christine Lind
28:47 - 30:07

Matthias. It's Christine. Thank you for the question. Uh, great questions as always. Uh, in terms of our new business development activities, yes, you're certainly right that the level of activity has increased significantly over the past. I guess I'll call it 12 to 18 months. With the transition of our business model from having our own product and production to being primarily focused on licensed partnerships. Uh, so the level of activity has certainly increased significantly. In line with that, we also see increasing interest and more activity in our early feasibility work and our discussions with partners around what early feasibility work could look like. Um, so hopefully we're giving a little bit of flavor there that, uh, we definitely are enthusiastic about the work that we see ongoing. Um, I, of course, want to make sure that I continue to exercise caution, as getting from our early feasibility work to actually having an announced exclusivity or license partner will, of course, be expected to take some time. Um, but we hope to be able to continue to show increased activities across our therapeutic areas on the pipeline snapshot that we presented earlier today as well. As we go forward.

Unknown 2
30:10 - 30:11

Thank you very much for that.

Christine Lind
30:13 - 30:14

Thank you Matthias.

Operator
30:16 - 30:39

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Christine Lind
30:42 - 30:59

Thank you for your great questions, as always, and for everyone's engagement and for listening in today. Uh, we look forward to our next opportunity to be able to update you on the progress in our business, and please do not hesitate to reach out to us. In the meantime, thank you for today and have a great day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…